Curium Group today announced that together with PeptiDream Inc. and PDRadiopharma Inc., the first patient has been dosed in the companies' registrational clinical trial of 177Lu-PSMA-I&T in Japan for ...
Opportunistic infections can contribute to antimicrobial resistance making these infections more severe than would occur otherwise. Some uninvolved pathogens that cause these infections possess ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results